# Double-Blind Trial of Everolimus for Improving Social Abilities in PTEN Germline Mutations

> **NCT07218575** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **Boston Children's Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Cowden's Disease
- Cowden's Syndrome
- Lhermitte-Duclos Disease
- Cerebellum Dysplastic Gangliocytoma
- Bannayan Zonana Syndrome
- Myhre Riley Smith Syndrome
- Riley Smith Syndrome
- PTEN Hamartoma Tumor Syndrome
- Bannayan Riley Ruvalcaba Syndrome

## Interventions

- **DRUG:** Everolimus blinded oral capsules
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07218575
- **Lead sponsor:** Boston Children's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2030-04
- **Final completion:** 2030-04
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07218575

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07218575, "Double-Blind Trial of Everolimus for Improving Social Abilities in PTEN Germline Mutations". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07218575. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*